BIOMAT Database Logo BIOMAT Database Logo

Tissue plasminogen activator: a new advancement in fibrinolytic therapy. 1986

B L Wescott

UI MeSH Term Description Entries
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013300 Streptokinase Streptococcal fibrinolysin . An enzyme produced by hemolytic streptococci. It hydrolyzes amide linkages and serves as an activator of plasminogen. It is used in thrombolytic therapy and is used also in mixtures with streptodornase (STREPTODORNASE AND STREPTOKINASE). EC 3.4.-. Avelizin,Awelysin,Celiase,Distreptase,Kabikinase,Kabivitrum,Streptase,Streptodecase

Related Publications

B L Wescott
Tissue-type plasminogen activator: a new fibrinolytic agent.
January 1987, Heart & lung : the journal of critical care,
B L Wescott
Recombinant tissue plasminogen activator (rt-PA) in fibrinolytic therapy.
April 1998, Journal of biotechnology,
B L Wescott
[Tissue plasminogen activator as a fibrinolytic agent].
January 1993, Polski tygodnik lekarski (Warsaw, Poland : 1960),
B L Wescott
[Tissue-type plasminogen activator--a fibrinolytic preparation].
January 1989, Farmakologiia i toksikologiia,
B L Wescott
[Fibrinolytic therapy--plasminogen activator inhibitors].
January 1988, VASA. Supplementum,
B L Wescott
Fibrinolytic therapy with low-dose recombinant tissue plasminogen activator in retinal vein occlusion.
January 1998, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde,
B L Wescott
Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
December 2012, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
B L Wescott
Tissue plasminogen activator-containing polyurethane surfaces for fibrinolytic activity.
May 2011, Acta biomaterialia,
B L Wescott
Tenecteplase (TNK tissue plasminogen activator): A new fibrinolytic for the acute treatment of myocardial infarction.
November 2001, Drugs of today (Barcelona, Spain : 1998),
B L Wescott
Hemorrhagic transformation after fibrinolytic therapy with tissue plasminogen activator in a rat thromboembolic model of stroke.
January 2000, Brain research,
Copied contents to your clipboard!